中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2015年
5期
393-397
,共5页
秦小琪%徐燕%安刚%秦宇%冯晓燕%隋伟薇%邓书会%藏美蓉%吕瑞
秦小琪%徐燕%安剛%秦宇%馮曉燕%隋偉薇%鄧書會%藏美蓉%呂瑞
진소기%서연%안강%진우%풍효연%수위미%산서회%장미용%려서
多发性骨髓瘤%β2微球蛋白%国际分期系统%肾功能
多髮性骨髓瘤%β2微毬蛋白%國際分期繫統%腎功能
다발성골수류%β2미구단백%국제분기계통%신공능
Multiple myeloma%beta 2-Microglobulin%International staging system%Renal function
目的 分析不同β2微球蛋白(β2-MG)水平合并或不合并肾功能异常的初诊多发性骨髓瘤(MM)患者的生存情况,探讨肾功能对β2微球蛋白作为MM预后因素的影响.方法 对1999年2月至201 3年10月666例初诊MM患者临床资料进行回顾性分析,以血肌酐＜177 μmol/L为肾功能相对正常组,血肌酐≥177 μmol/L为肾功能异常组,分析不同β2-MG水平及肾功能状态患者总生存(OS)情况.结果 666例患者中男416例,女250例,中位年龄58(25～86)岁.β2-MG＜3.5、3.5～＜5.5及≥5.5 mg/L患者分别为208、173及285例,其OS时间分别为85.75 (95％ CI 70.99～100.50)、47.25 (95％ CI 40.98～53.53)及35.05(95％CI30.75～39.35)个月,差异有统计学意义(P＜0.01).肾功能相对正常与肾功能异常患者OS时间分别为64.67(95％CI56.57～72.77)及32.74(95％CI27.74～37.73)个月,差异有统计学意义(P＜0.01).在β2-MG≥5.5 mg/L的患者中,肾功能相对正常与肾功能异常患者OS时间分别为37.25(95％ CI 31.45～43.06)个月、32.55(95％ CI26.26～38.83)个月,差异无统计学意义(P=0.142).结论 高水平β2-MG、肾功能异常MM患者生存时间较短,是否合并肾功能异常并未改变β2-MG作为MM国际分期系统预后因素的影响.
目的 分析不同β2微毬蛋白(β2-MG)水平閤併或不閤併腎功能異常的初診多髮性骨髓瘤(MM)患者的生存情況,探討腎功能對β2微毬蛋白作為MM預後因素的影響.方法 對1999年2月至201 3年10月666例初診MM患者臨床資料進行迴顧性分析,以血肌酐＜177 μmol/L為腎功能相對正常組,血肌酐≥177 μmol/L為腎功能異常組,分析不同β2-MG水平及腎功能狀態患者總生存(OS)情況.結果 666例患者中男416例,女250例,中位年齡58(25～86)歲.β2-MG＜3.5、3.5～＜5.5及≥5.5 mg/L患者分彆為208、173及285例,其OS時間分彆為85.75 (95％ CI 70.99～100.50)、47.25 (95％ CI 40.98～53.53)及35.05(95％CI30.75～39.35)箇月,差異有統計學意義(P＜0.01).腎功能相對正常與腎功能異常患者OS時間分彆為64.67(95％CI56.57～72.77)及32.74(95％CI27.74～37.73)箇月,差異有統計學意義(P＜0.01).在β2-MG≥5.5 mg/L的患者中,腎功能相對正常與腎功能異常患者OS時間分彆為37.25(95％ CI 31.45～43.06)箇月、32.55(95％ CI26.26～38.83)箇月,差異無統計學意義(P=0.142).結論 高水平β2-MG、腎功能異常MM患者生存時間較短,是否閤併腎功能異常併未改變β2-MG作為MM國際分期繫統預後因素的影響.
목적 분석불동β2미구단백(β2-MG)수평합병혹불합병신공능이상적초진다발성골수류(MM)환자적생존정황,탐토신공능대β2미구단백작위MM예후인소적영향.방법 대1999년2월지201 3년10월666례초진MM환자림상자료진행회고성분석,이혈기항＜177 μmol/L위신공능상대정상조,혈기항≥177 μmol/L위신공능이상조,분석불동β2-MG수평급신공능상태환자총생존(OS)정황.결과 666례환자중남416례,녀250례,중위년령58(25～86)세.β2-MG＜3.5、3.5～＜5.5급≥5.5 mg/L환자분별위208、173급285례,기OS시간분별위85.75 (95％ CI 70.99～100.50)、47.25 (95％ CI 40.98～53.53)급35.05(95％CI30.75～39.35)개월,차이유통계학의의(P＜0.01).신공능상대정상여신공능이상환자OS시간분별위64.67(95％CI56.57～72.77)급32.74(95％CI27.74～37.73)개월,차이유통계학의의(P＜0.01).재β2-MG≥5.5 mg/L적환자중,신공능상대정상여신공능이상환자OS시간분별위37.25(95％ CI 31.45～43.06)개월、32.55(95％ CI26.26～38.83)개월,차이무통계학의의(P=0.142).결론 고수평β2-MG、신공능이상MM환자생존시간교단,시부합병신공능이상병미개변β2-MG작위MM국제분기계통예후인소적영향.
Objective To investigate the influence of renal function on the level of β2-microglobulin (β2-MG) as prognostic factor in newly diagnosed multiple myeloma (MM) patients,and to analyze the overall survival (OS) in different level of β2-MG with relatively normal or abnormal renal function in MM patients.Methods According to the level of β2-MG,666 newly diagnosed MM patients were divided into three groups as β2-MG＜3.5,3.5-＜5.5,≥5.5 mg/L.According to the level of serum creatinine,these patients were divided into two groups:serum creatinine ＜177 μmol/L as relatively normal group,serum creatinine ≥177 μmol/L as abnormal group.Results Among 666 patients,there were 416 male and 250 female,the median age was 58 (25-86) years old.Comparison of OS among β2-MG＜3.5,3.5-＜5.5,≥5.5 mg/L groups indicated that the median OS of the three groups were 85.75 (95％ CI 70.99-100.50),47.25 (95％ CI 40.98-53.53) and 35.05 (95％ CI 30.75-39.35) months,respectively (P＜0.01).Comparison of OS between serum creatinine ＜177 and ≥177 mmol/L groups,the median OS of the two groups were 64.67 (95％ CI 56.57-72.77) and 32.74 (95％ CI 27.74-37.73) months,respectively (P＜ 0.01).In β2-MG≥5.5 mg/L,the median OS of relatively normal and abnormal groups were 37.25 (95％ CI 31.45-43.06) and 32.55(95％ CI 26.26-38.83) months,respectively (P=0.142).Conclusions High level of β2-MG and renal function correlated with shorter survival of MM patients.Higher level of β2-MG with abnormal renal function can't change the prognostic value of β2-microglobulin on MM.
